tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Jain A et al. Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations. 2001 Feb-Mar Transplant. Proc. pmid:11267319
Mueller AR et al. Influence of immunosuppression on patient survival after liver transplantation for hepatitis C. 2001 Feb-Mar Transplant. Proc. pmid:11267321
Mohamed MA et al. TGF-beta expression in protocol transplant liver biopsies: a comparative study between cyclosporine-A (CyA) and tacrolimus (FK 506) immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267336
Shokouh-Amiri MH et al. The importance of early prevention of renal dysfunction in liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267345
Markus BH et al. Daclizumab induction therapy in combination with tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267354
Langrehr JM et al. IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267360
Heffron TG et al. Single-dose induction with daclizumab immediately after liver transplantation in pediatric patients. 2001 Feb-Mar Transplant. Proc. pmid:11267368
Groetzner J et al. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? 2001 Feb-Mar Transplant. Proc. pmid:11267373
van den Berg AP et al. Recurrent HCV infection reduces the requirement for tacrolimus after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267375
Pirenne J et al. Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267396
Langrehr JM et al. A prospective, randomized trial with quadruple versus dual tacrolimus-based induction after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267404
Heffron TG et al. Daclizumab induction in liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267408
Rabkin JM et al. Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267411
Uber PA et al. Ethnic disparities in the pharmacologic characteristics of tacrolimus in heart transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267428
Banerjee R et al. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267435
Mehra MR et al. A randomized comparison of an immunosuppressive strategy using tacrolimus and cyclosporine in black heart transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267438
Mehra MR et al. Racial differences in clinical outcome using tacrolimus and mycophenolate mofetil immunosuppression in heart transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267442
Treede H et al. Incidence and spectrum of infections in lung transplanted patients: comparison of four different immunosuppressive protocols. 2001 Feb-Mar Transplant. Proc. pmid:11267444
Jordan ML et al. Steroid withdrawal for pancreas transplants under tacrolimus immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267456
Lo A et al. Outcome of simultaneous kidney-pancreas transplantation in African-American recipients: a case control study. 2001 Feb-Mar Transplant. Proc. pmid:11267465
Burke GW et al. Ten-year survival after simultaneous pancreas/kidney transplantation with bladder drainage and tacrolimus-based immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267467
Kahl A et al. Long-term prednisolone withdrawal after pancreas and kidney transplantation in patients treated with ATG, tacrolimus, and mycophenolate mofetil. 2001 Feb-Mar Transplant. Proc. pmid:11267473
McCauley J et al. Long-term lipid metabolism in combined kidney-pancreas transplant recipients under tacrolimus immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267475
Lo A et al. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267477
Owen ER et al. Peripheral nerve regeneration in human hand transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267484
Molmenti EP et al. Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267487
Spada M et al. A cause of late graft dysfunction after liver transplantation in children: de-novo autoimmune hepatitis. 2001 Feb-Mar Transplant. Proc. pmid:11267495
Lo A et al. Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone. 2001 Feb-Mar Transplant. Proc. pmid:11267516
Reimer J et al. Quality of life after kidney transplantation--the impact of tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267573
Jain A et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. 2001 J Clin Pharmacol pmid:11269567
Bekersky I et al. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. 2001 J Clin Pharmacol pmid:11269569
Ericzon B et al. Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study. 1994 Transpl. Int. pmid:11271178
Undre N and Möller A Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group. 1994 Transpl. Int. pmid:11271189
Yano K et al. Effects of intrahepatic arterial and intraportal administration of FK 506 on liver allograft survival in rats. 1994 Transpl. Int. pmid:11271200
Devlin J et al. Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipients. 1994 Transpl. Int. pmid:11271207
Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group. 1994 Transpl. Int. pmid:11271216
Neuhaus P et al. Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. 1994 Transpl. Int. pmid:11271222
Bismuth H et al. Focus on intractable rejection: 6-month results of the European multicentre liver study of FK 506 and cyclosporin A. 1994 Transpl. Int. pmid:11271231
McMaster P Patient and graft survival in the European Multicentre Liver Study--FK 506 vs cyclosporin A. 1994 Transpl. Int. pmid:11271239
Mueller AR et al. Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients. 1994 Transpl. Int. pmid:11271254
D'Silva M et al. The immunomodulatory effects of a novel agent, leflunomide, in rat cardiac allotransplantation. 1994 Transpl. Int. pmid:11271257
Trocha K et al. Neurological examinations after liver transplantation concerning patients under corticosteroid immunosuppression and either FK 506 or cyclosporin. 1994 Transpl. Int. pmid:11271273
Ishii T et al. Immunodepressants ameliorate normothermic ischemia injury to the rat liver by down-regulating tumor necrosis factor, not by alleviation of lipid peroxidative injury. 1994 Transpl. Int. pmid:11271294
Platz KP et al. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients. 1994 Transpl. Int. pmid:11271297
Metcalfe S et al. FK 506 and cyclosporin each block antigen-induced T cell receptor signalling that is dependent on CD4 co-receptor and operates in the absence of detectable cytoplasmic calcium fluxes. 1994 Transpl. Int. pmid:11271304
Moutabarrik A et al. Effect of immunosuppressive agents FK 506 and cyclosporin and steroids on the expression of IL-6 and its receptor by stimulated lymphocytes and monocytes. 1994 Transpl. Int. pmid:11271305
Winkler M et al. Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation. 1994 Transpl. Int. pmid:11271312
Devlin J et al. FK 506 primary immunosuppression following emergency liver transplantation for fulminant hepatic failure. European FK 506 Study Liver Group. 1994 Transpl. Int. pmid:11271328
Otto G et al. Corticosteroids and concomitant medication in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. 1994 Transpl. Int. pmid:11271338
Wong P et al. FK 506 rescue therapy for intractable liver allograft rejection. 1994 Transpl. Int. pmid:11271339